{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:25:29Z","timestamp":1777429529118,"version":"3.51.4"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00393-025-01765-2","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T11:33:27Z","timestamp":1770032007000},"page":"317-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Filgotinib gegen Kalzinose bei Zentromer-Antik\u00f6rper-positiver systemischer Sklerose","Filgotinib treatment of calcinosis in centromere-antibody-positive systemic sclerosis"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-4818","authenticated-orcid":false,"given":"Ottar","family":"Gadeholt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"1","key":"1765_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo\u00a0F, Lescoat\u00a0A, Conaghan\u00a0PG, Bertoldo\u00a0E, \u010coli\u0107\u00a0J, Santiago\u00a0T, Suliman\u00a0YA, Matucci-Cerinic\u00a0M, Gabrielli\u00a0A, Distler\u00a0O, Hoffmann-Vold\u00a0AM, Castellv\u00ed\u00a0I, Balbir-Gurman\u00a0A, Vonk\u00a0M, Ananyeva\u00a0L, Rednic\u00a0S, Tarasova\u00a0A, Ostojic\u00a0P, Boyadzhieva\u00a0V, El Aoufy\u00a0K, Farrington\u00a0S, Galetti\u00a0I, Denton\u00a0CP, Kowal-Bielecka\u00a0O, Mueller-Ladner\u00a0U, Allanore\u00a0Y (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340. https:\/\/doi.org\/10.1136\/ard-2024-226430","journal-title":"Ann Rheum Dis"},{"key":"1765_CR2","unstructured":"S2k Leitlinie \u201eDiagnostik und Therapie der systemischen Sklerose\u201c. https:\/\/register.awmf.org\/assets\/guidelines\/060-014l_S2k_Diagnostik_Therapie_systemische_Sklerose_2025-07_1.pdf"},{"issue":"10","key":"1765_CR3","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","volume":"55","author":"CP Denton","year":"2016","unstructured":"Denton\u00a0CP, Hughes\u00a0M, Gak\u00a0N, Vila\u00a0J, Buch\u00a0MH, Chakravarty\u00a0K, Fligelstone\u00a0K, Gompels\u00a0LL, Griffiths\u00a0B, Herrick\u00a0AL, Pang\u00a0J, Parker\u00a0L, Redmond\u00a0A, van Laar\u00a0J, Warburton\u00a0L, Ong\u00a0VH (2016) BSR and BHPR guideline for the treatment of systemic sclerosis. Baillieres Clin Rheumatol 55(10):1906\u20131910. https:\/\/doi.org\/10.1093\/rheumatology\/kew224 (the BSR and BHPR Standards, Guidelines and Audit Working Group)","journal-title":"Baillieres Clin Rheumatol"},{"issue":"1","key":"1765_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","volume":"51","author":"LS Simon","year":"2021","unstructured":"Simon\u00a0LS, Taylor\u00a0PC, Choy\u00a0EH, Sebba\u00a0A, Quebe\u00a0A, Knopp\u00a0KL, Porreca\u00a0F (2021) The Jak\/STAT pathway: a\u00a0focus on pain in rheumatoid arthritis. Semin Arthritis Rheum 51(1):278\u2013284. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.10.008","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1765_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13075-023-03170-z","volume":"25","author":"J Zhang","year":"2023","unstructured":"Zhang\u00a0J, Sun\u00a0L, Shi\u00a0X, Li\u00a0S, Liu\u00a0C, Li\u00a0X, Lu\u00a0M, Deng\u00a0J, Tan\u00a0X, Guan\u00a0W, Li\u00a0G, Wen\u00a0X, Liu\u00a0P, Li\u00a0C (2023) Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a\u00a0retrospective multi-central study in China. Arthritis Res Ther 25(1):204. https:\/\/doi.org\/10.1186\/s13075-023-03170-z","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1765_CR6","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1093\/rheumatology\/keab421","volume":"60","author":"M Shneyderman","year":"2021","unstructured":"Shneyderman\u00a0M, Ahlawat\u00a0S, Christopher-Stine\u00a0L, Paik\u00a0JJ (2021) Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a\u00a0case series. Rheumatology 60(11):e387\u2013e388. https:\/\/doi.org\/10.1093\/rheumatology\/keab421","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01765-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01765-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:38:58Z","timestamp":1777376338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01765-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1765"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01765-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"O.\u00a0Gadeholt bekam 2022 Reiseunterst\u00fctzung von Galapagos, die Firma, die zu dieser Zeit Filgotinib vertrieb. Galapagos hatten keine Kenntnisse \u00fcber die Durchf\u00fchrung dieser Therapie und hatte \u00fcber die Therapieentscheidung keinen Einfluss.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die Patientin wurde \u00fcber den eingereichten Artikel informiert und hatte Gelegenheit, ihn vollst\u00e4ndig zu lesen. Sie hat m\u00fcndlich und schriftlich ihre Zustimmung zur Einreichung des Manuskripts gegeben und freut sich, einen Beitrag leisten zu k\u00f6nnen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einverst\u00e4ndniserkl\u00e4rung der Patientin"}}]}}